Zevra Therapeutics (ZVRA) Receivables - Other (2018 - 2024)
Zevra Therapeutics' Receivables - Other history spans 8 years, with the latest figure at $333000.0 for Q4 2024.
- For Q4 2024, Receivables - Other fell 73.53% year-over-year to $333000.0; the TTM value through Dec 2024 reached $333000.0, down 73.53%, while the annual FY2024 figure was $333000.0, 73.53% down from the prior year.
- Receivables - Other reached $333000.0 in Q4 2024 per ZVRA's latest filing, down from $1.3 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $1.3 million in Q4 2023 to a low of $107000.0 in Q4 2021.
- Average Receivables - Other over 5 years is $528363.6, with a median of $400000.0 recorded in 2020.
- Peak YoY movement for Receivables - Other: surged 941.12% in 2022, then crashed 73.53% in 2024.
- A 5-year view of Receivables - Other shows it stood at $400000.0 in 2020, then tumbled by 73.25% to $107000.0 in 2021, then soared by 941.12% to $1.1 million in 2022, then grew by 12.93% to $1.3 million in 2023, then plummeted by 73.53% to $333000.0 in 2024.
- Per Business Quant, the three most recent readings for ZVRA's Receivables - Other are $333000.0 (Q4 2024), $1.3 million (Q4 2023), and $700000.0 (Q1 2023).